VBI Vaccines Inc. (VBIV) Aktienanalyse

VBI Vaccines Inc. (VBIV) Gesundheitswesen & Pipeline-Uebersicht

VBI Vaccines is a biopharmaceutical innovator leveraging its unique eVLP platform to develop next-generation vaccines for infectious diseases and immuno-oncology, offering a notable research candidate driven by its Sci-B-Vac sales and promising pipeline of vaccine candidates.

Investmentthese

VBI Vaccines presents a notable research candidate based on its established Sci-B-Vac revenue stream, innovative eVLP platform, and promising pipeline of vaccine candidates targeting significant unmet medical needs. The company's immunotherapeutic candidate, VBI-2601, for chronic HBV infection, represents a substantial market opportunity, particularly if clinical trials demonstrate significant efficacy. Furthermore, the glioblastoma vaccine immunotherapeutic, VBI-1901, offers potential upside in the immuno-oncology space. Successful advancement of these pipeline assets, coupled with continued Sci-B-Vac sales, could drive significant revenue growth and shareholder value. The collaborations with Brii Biosciences and other organizations also de-risk the development process and provide access to additional resources and expertise. Investors should monitor clinical trial results and regulatory milestones as key value drivers.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

• Sci-B-Vac is a commercially available prophylactic hepatitis B (HBV) vaccine.
• eVLP platform technology allows for the development of vaccines that mimic the presentation of viruses to elicit a human immune system.
• VBI-2601 (BRII-179) is an immunotherapeutic candidate for the treatment of chronic HBV infection.
• VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, is in Phase I/IIa clinical study.
• VBI collaborates with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome.

Wettbewerber & Vergleichsunternehmen

Staerken

• Proprietary eVLP platform technology.
• Commercially available hepatitis B vaccine (Sci-B-Vac).
• Strong pipeline of vaccine candidates.
• Strategic collaborations with leading organizations.

Schwaechen

• Negative profit margin and limited financial resources.
• Dependence on successful clinical trial outcomes.
• Competition from larger pharmaceutical companies.
• Geographic concentration of Sci-B-Vac sales.

Katalysatoren

• Upcoming: Phase III data readout for VBI-2601 in chronic HBV infection.
• Upcoming: Initiation of Phase II clinical trial for VBI-1901 in glioblastoma.
• Ongoing: Expansion of Sci-B-Vac sales in existing and new markets.
• Ongoing: Progress in the development of coronavirus vaccine candidates.
• Ongoing: Potential for new licensing and collaboration agreements.

Risiken

• Potential: Clinical trial failures for pipeline candidates.
• Potential: Regulatory delays or non-approval of vaccine candidates.
• Ongoing: Competition from larger pharmaceutical companies with greater resources.
• Ongoing: Dependence on key partnerships and collaborations.
• Potential: Negative gross and profit margins.

Wachstumschancen

• Expansion of Sci-B-Vac Market: VBI has the opportunity to expand the market reach of Sci-B-Vac beyond its current territories. The global hepatitis B vaccine market is projected to reach billions of dollars, and increasing vaccination rates in developing countries could provide a significant growth opportunity for VBI. Timeline: Ongoing.
• Advancement of VBI-2601 (BRII-179): The development of VBI-2601 as an immunotherapeutic for chronic HBV infection represents a substantial growth driver. Success in clinical trials and subsequent regulatory approval could lead to significant revenue generation. The chronic HBV market is a multi-billion dollar market with a significant unmet need for effective therapies. Timeline: 2-3 years for Phase III data.
• Development of VBI-1901 for Glioblastoma: VBI-1901, a glioblastoma vaccine immunotherapeutic, offers potential in the immuno-oncology space. Positive results from the ongoing Phase I/IIa clinical study could lead to further development and commercialization, addressing a critical need in the treatment of this aggressive brain cancer. The glioblastoma treatment market is expected to grow, driven by the need for more effective therapies. Timeline: 3-5 years for potential commercialization.
• Coronavirus Vaccine Development: VBI's efforts in developing coronavirus vaccine candidates, such as VBI-2902 and VBI-2901, present a growth opportunity in addressing current and future coronavirus variants. Collaborations with organizations like CEPI and the National Research Council of Canada could accelerate development and deployment. The market for coronavirus vaccines remains significant, driven by the ongoing need for booster shots and protection against new variants. Timeline: Ongoing research and development.
• Licensing and Collaboration Agreements: VBI can leverage its eVLP platform to develop vaccine platforms and products for licensing to pharmaceutical and biotechnology companies. This strategy allows for diversification of revenue streams and reduces the financial risk associated with individual vaccine development programs. The market for vaccine technology licensing is robust, with pharmaceutical companies seeking innovative platforms to enhance their vaccine development efforts. Timeline: Ongoing.

Chancen

• Expansion of Sci-B-Vac market reach.
• Successful development and commercialization of pipeline candidates.
• Licensing and collaboration agreements for eVLP platform.
• Growing demand for vaccines and immunotherapies.

Risiken

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from established vaccine manufacturers.
• Changes in healthcare policies and reimbursement.

Wettbewerbsvorteile

• eVLP Platform Technology: VBI's proprietary eVLP platform provides a competitive advantage in developing novel vaccines that elicit a strong immune response.
• Sci-B-Vac: Established market presence and brand recognition for Sci-B-Vac in certain regions.
• Strategic Collaborations: Partnerships with Brii Biosciences, GlaxoSmithKline, and other organizations provide access to resources and expertise.
• Pipeline of Vaccine Candidates: A diverse pipeline of vaccine candidates targeting significant unmet medical needs.

Ueber VBIV

VBI Vaccines Inc., originally SciVac Therapeutics Inc. until its rebranding in 2016, is a biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing and commercializing vaccines to address significant unmet needs in infectious diseases and immuno-oncology. The company's foundation is built upon its enveloped virus-like particle (eVLP) platform technology, which allows for the creation of vaccines that closely mimic the natural presentation of viruses to the human immune system, thereby eliciting a robust and targeted immune response. VBI's commercial product is Sci-B-Vac, a third-generation prophylactic hepatitis B (HBV) vaccine that is currently marketed. In addition to Sci-B-Vac, VBI is advancing a pipeline of vaccine candidates, including VBI-2601 (BRII-179), an immunotherapeutic candidate for chronic HBV infection being developed in collaboration with Brii Biosciences. Other key programs include VBI-1901, a glioblastoma vaccine immunotherapeutic in Phase I/IIa clinical study, and VBI-1501, a prophylactic cytomegalovirus (CMV) vaccine candidate that has completed Phase I clinical trial. VBI is also actively involved in developing coronavirus vaccine candidates, such as VBI-2902 and VBI-2901, and collaborates with organizations like the National Research Council of Canada and the Coalition for Epidemic Preparedness Innovations (CEPI) to advance pan-coronavirus vaccine development. Through strategic collaborations and a focus on innovative vaccine technologies, VBI Vaccines aims to establish itself as a leader in the prevention and treatment of infectious diseases and cancer.

Was das Unternehmen tut

• Develop and sell vaccines for infectious diseases.
• Develop immunotherapies for cancer.
• Offer Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine.
• Develop VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
• Utilize their enveloped virus-like particle (eVLP) platform technology to create novel vaccines.
• Develop coronavirus vaccine candidates, such as VBI-2902 and VBI-2901.
• Engage in collaborations and license agreements with pharmaceutical and biotechnology companies.
• Develop vaccine platforms and products for licensing to other companies.

Geschaeftsmodell

• Develop and commercialize vaccines for infectious diseases and immuno-oncology.
• Generate revenue through sales of Sci-B-Vac.
• Out-license vaccine technologies and candidates to other pharmaceutical companies.
• Collaborate with other organizations to develop and commercialize vaccines.

Branchenkontext

VBI Vaccines operates within the biotechnology industry, which is characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. The global vaccine market is experiencing significant growth, driven by increasing awareness of preventative healthcare, rising incidence of infectious diseases, and advancements in vaccine technology. VBI's eVLP platform and focus on unmet medical needs position it to capture a share of this growing market. Competitors include companies developing vaccines for similar indications, as well as larger pharmaceutical companies with established vaccine franchises.

Wichtige Kunden

• Individuals seeking protection against hepatitis B.
• Patients with chronic HBV infection.
• Patients with glioblastoma.
• Pharmaceutical companies licensing VBI's vaccine technologies.

Finanzdaten

Chart & Info

Aktuelle Nachrichten

Analystenkonsens

MoonshotScore

Was Anleger ueber VBI Vaccines Inc. (VBIV) wissen wollen

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Popular Stocks